Sponsor

Kite Pharma Inc.

United States 2400 Broadway, 90404-3030, United States

About the sponsor

Kite Pharma Inc. focuses extensively on relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, indolent non-Hodgkin lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma, and Richter transformation.

Relapsed/refractory B-cell non-Hodgkin lymphoma
First-line high-risk large B-cell lymphoma
Follicular lymphoma
Rare B-cell malignancies

The portfolio also includes studies in Waldenstrom macroglobulinemia and hairy cell leukemia, reflecting a strong interest in difficult-to-treat mature B-cell disorders.

About Specializations

Kite Pharma Inc. runs clinical trials in conditions such as Follicular lymphoma, Haematological malignancy, Plasma cell myeloma refractory, Non-Hodgkin's lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

11 clinical trials

Haematological malignancy

Recruiting

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo

Austria

Participants:0–17 years · 18–64 years · 65+ years
Substances:Axicabtagene Ciloleucel
Sponsor:Kite Pharma Inc.

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study Comparing Anitocabtagene Autoleucel with Standard Treatment for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Kite Pharma Inc.

Contact Research Centre

Follicular lymphoma

Not recruiting

Study Comparing Axicabtagene Ciloleucel with Standard Treatment for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

Study Comparing Axicabtagene Ciloleucel with Standard Treatment for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Kite Pharma Inc.

Contact Research Centre

Non-Hodgkin's lymphoma+2

Not recruiting

Study on the Safety and Effectiveness of Brexucabtagene Autoleucel for Children and Teens with Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Registered drugNo placebo